Centre Hospitalier De Cannes Simone Veil — Clinical Trial Site

19 Registered trials

9 Currently recruiting

Organisation

Centre Hospitalier De Cannes Simone Veil

Location

Cannes Cedex, France

Identifier

ORG-100045195

Address

15 Avenue Des Broussailles, Cs 50008, 06414, France

Departments

ICU
Médecine Intensive et Réanimation
Médecine Interne Infectiologie
oncology
Oncology department
Pneumologie
Pneumology
RHUMATOLOGY
Service de Médecine Intensive Réanimation
Service de Pneumologie
Service Pneumologie

Clinical trials at this site (19)

Search interface

Osteoarticular infections on prosthesis: impact of three antibiotic therapies on the digestive microbiota Pending

2024-513298-29-00 Osteoarticular infections on equipment 4
BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/… Pending

2025-524289-56-00 Asthma 6
Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial Pending

2025-524976-40-00 patients with influenza-induced acute hypoxemic respira 5
Methotrexate treatment in hand osteoarthritis refractory to usual treatments Recruiting

2022-502362-24-00 Erosive osteoarthritis 4 2026-06-30
WIthdrawal of DUpilumab in Severe Asthma : a randomised non-inferiority-controlled trial Recruiting

2024-516789-13-00 Severe asthma 6 2025-12-15
AKAPI: Amikacin Liposome Inhalation Suspension for treatment of Mycobacterium xenopi pulmonary infection: A prospective controlled open-labe… Recruiting

2023-506843-40-00 Mycobacterium xenopi pulmonary infection 5 2025-10-29
Fluid administration in ketoacidosis Recruiting

2024-511513-37-00 Diabetic keto-acidosis 6 2025-10-23
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C… Recruiting

2023-507407-59-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-07-04
A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting

2022-502113-28-00 Follicular lymphoma 5 2024-02-01
A phase II-III randomized trial evaluating maintenance pembrolizumab (± pemetrexed) until progression versus observation (± pemetrexed) afte… Recruiting

2024-515945-40-00 Non small cell lung cancer 10 2022-05-02
PD-(L)1 iNhibitors with concurrent IRadiation at VAried tumour sites in advanced Non-small cell lung cAncer Recruiting

2024-512173-27-00 Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible f 5 2019-03-21
CLAZI : CLArithromycin versus AZIthromycin in the treatment of Mycobacterium avium complex pulmonary infections: A randomized prospective co… Recruiting

2024-518578-15-00 Is to demonstrate a non inferior efficacy of azithromyc 5 2018-02-05
REIMAGINE – Real-world EvaluatIon of Mepolizumab in severe Asthma achievinG on treatment clinIcal remissioN, a prospEctive study. Ended

2023-509026-21-00 severe asthma 6 2024-06-03
Phase III randomized trial of atezolizumab in elderly patients with advanced Non-Small-Cell Lung Cancer and receiving monthly carboplatin wi… Ended

2024-515946-17-00 Non Small Cell Lung Cancer 5 2019-07-22
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patient… Ended

2024-518741-21-00 colon cancer 4 2014-12-23
A study to assess and compare safety and tolerability of 3 months treatment with salbutamol administered via MDI containing propellant HFA-1… Ended

2023-509001-76-00 Asthma 5 2024-07-01
A study of GSK3511294 (Depemokimab) in participants who were previously enrolled in 206713 or 213744; Open-Label Extension Ended

2023-505203-23-01 Severe asthma with an eosinophilic phenotype 5 2021-07-26
Adjunctive DobutAmine in sePtic cardiomyopathy with Tissue hypoperfusion: a randomized controlled multi-center trial Ended

2024-517839-50-00 sepsis 11 2020-09-20
Trial comparing the continuation of nivolumab and ipilimumab (doublet immunotherapy) to observation after a first 6 months treatment by nivo… Ended

2024-514586-20-01 Non small cell lung cancer 5 2018-05-02